Komori
Kohjin Bio (177A) · FactAdvanced

Listing on the Tokyo Stock Exchange Growth Market and growth investment

First written in FY2024. 4 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.

5entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025-H1 – FY20262024: 220242025: 220252026: 12026
Same theme, other companies
Public Offering and Third-Party Allotment Capital Increase to Fund Capital Investment and Debt RepaymentA theme 92 companies write about · 1 as a headwind · 96 as a tailwind

30 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 92 companies compared. The sentences above are computed from all 92.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Total capital investment for the consolidated fiscal year was ¥1,043 million. Major items included the remaining construction costs for the warehouse and staff break room and changing room facilities, construction work and installed equipment for the cell processing facility scheduled to be newly established on the fifth floor of the warehouse, and land acquired in Nagasaki Prefecture for construction of a new plant.」

    As growth investment following the listing and capital increase, the company is proceeding with capital investment in warehouses and other facilities, a cell processing facility and plant construction land in Nagasaki Prefecture.
  2. FY2026-H1AdvancedAnnual report

    「During the interim consolidated accounting period, the following major capital expenditure projects that had been planned at the end of the previous consolidated fiscal year were completed.」

    As growth investment funded by the listing and capital increase, the planned warehouse and staff break room and changing room facilities at the head office were completed in September 2025.
  3. FY2025AdvancedAnnual report

    「Funds obtained through financing activities during the consolidated fiscal year amounted to ¥1,376 million. This was mainly attributable to proceeds of ¥1,653 million from the issuance of shares associated with the new listing and third-party allotment.」

    Funds raised through the listing and third-party allotment were reflected in full-year financing activities, and funds were invested in growth initiatives such as warehouse construction.
  4. FY2025-H1AdvancedAnnual report

    「This was primarily due to an increase of ¥1,579 million in cash and deposits resulting from the listing of the company's shares on the Tokyo Stock Exchange Growth Market, the payment associated with the issuance of new shares through a third-party allotment and related transactions.」

    Funds raised through the listing and third-party allotment have been reflected in the accounts, with funds being invested in growth initiatives such as the initial costs of constructing a new warehouse.
  5. FY2024First statedAnnual report

    「The company was listed on the Tokyo Stock Exchange Growth Market on 25 April 2024.」

    Funds raised through the public offering and third-party allotment are planned to be allocated to a warehouse, core systems, powder culture media equipment and disaster-prevention equipment.
Moved together

"Expansion of Production Facilities and Strengthening of R&D Capabilities" moved the same way as this thread, in the same document, in 4 of its 5 moves.

443222★123456
  1. ★This thread
  2. 1Expansion of Production Facilities and Strengthening of R&D Capabilities4×
  3. 2Expansion of the Regenerative Medicine Market4×
  4. 3Entry into Contract Manufacturing of Cells for Clinical Trials of Regenerative Medical Products3×
  5. 4Expansion of Culture Media Product Lineup, Production Technology and Sales Organization2×
  6. 5Development and commercial launch of media for CHO and HEK293 cells2×
  7. 6Development and launch of rapid infectious disease test kits for Asia2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kohjin Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Listing on the Tokyo Stock Exchange Growth Market and growth investment | Kohjin Bio Co.,Ltd. (177A) | Komori